Rheum for Children: Pediatric Dermatology and Co-Grant Program (USA) by info.odysseyx@gmail.com November 6, 2024 written by info.odysseyx@gmail.com November 6, 2024 0 comment 1 views 1 Arthritis National Research Foundation and Pediatric Dermatology Research Alliance to provide financial support to early career researchers studying diseases affecting pediatric joints and skin within seven years, 2025 We are pleased to announce the launch of Rheum for Children: Pediatric Dermatology and Joint Grants. Their latest training phase. The Pediatric Dermatology Research Alliance (PeDRA) provides a platform for pediatric dermatologists to organize and collaborate on research, while also supporting individuals undertaking early-stage research that may or may not benefit from future collaborations. It’s a network. Pooling resources and connecting researchers with one another multiplies the power of each individual clinician-scientist many times over. With more than 600 members representing more than 180 institutions, PeDRA accelerates research and brings us closer to new treatment opportunities for children and families with skin conditions and diseases. target PeDRA and ANRF are committed to training the next generation of leaders in pediatric skin and joint disease research. They are pleased to offer the opportunity to support early career researchers pursuing innovative and impactful research projects. The goal is to develop an interdisciplinary research team encompassing pediatric dermatology and pediatric rheumatology to advance impactful research efforts. range This request addresses issues related to pediatric rheumatology and dermatology, including but not limited to juvenile arthritis, psoriasis, lupus, dermatomyositis, morphea, or the underlying mechanisms that may contribute to these or other conditions that affect both the skin and joints. Applies to all types of applications. Candidates for the Rheum for Kids: Pediatric Skin and Joint Grant are qualified, promising researchers with a clear upward trajectory, ideally within seven years of their most recent stage of training, and can demonstrate a strong mentoring support system. funds information Grants are for one year and are worth up to $50,000. Eligibility Criteria Clinical and basic/fundamental research will be considered. Clinical research must have a translational component to help uncover the underlying mechanisms or response to treatment. You may submit one application per person or laboratory each year. Interested applicants are encouraged to discuss their intention to apply with their lab, mentor, or supervisor. If multiple applicants from the same lab submit applications, only the first submitted application will be reviewed. Researchers must have an MD and/or Ph.D. Degree or equivalent. Applicants do not have to be U.S. citizens. Applicants must be affiliated with an eligible U.S. non-profit research organization and complete all grant-funded research. Preference is given to postdocs, research associates, and early career researchers who transition to independent investigator status within seven years of postdoctoral training. Applicant may or may not have received an NIH RO1 grant or equivalent. Please do not apply if you have received NIH RO1 or equivalent support. For more information, please visit: ANRF. Share 0 FacebookTwitterPinterestEmail info.odysseyx@gmail.com previous post Submit application for postdoctoral fellowship program (USA) next post CFA: 6th Anglo-German Humanities Pioneers Symposium “Affiliation” You may also like How to Build Trust in Proposal Writing – Funding for NGOs November 7, 2024 CFA: 6th Anglo-German Humanities Pioneers Symposium “Affiliation” November 6, 2024 Submit application for postdoctoral fellowship program (USA) November 6, 2024 Psoriatic Arthritis Research Grant Program (USA) November 6, 2024 Creating a Persuasive Grant Budget: Do’s and Don’ts November 6, 2024 Write a scholarship essay that captivates reviewers November 6, 2024 Leave a Comment Cancel Reply Save my name, email, and website in this browser for the next time I comment.